To elucidate the immune protection mechanism of emerging and re-emerging infectious diseases, immunoevaluation is a key step in the discovery and development of innovative vaccines. Through this platform, companies can select the best combination of antigens and adjuvants to improve immunogenicity. Immunoevaluation involves many subjects such as immunology, biology, molecular biology and clinical chemistry. The core scientific team of the company started to build the immune evaluation platform as early as 2004, and Recbio is one of the first teams to have this platform in China. Through this platform, the company became one of the first companies in China to be able to conduct fake virus neutralization, ELISPOT and ICS tests, which have been used in our vaccine candidate development, demonstrating the company's strong R&D capabilities.